&Partners Increases Stock Position in Eli Lilly and Company (NYSE:LLY)

15 Dec 2023, 18:16 by Teresa Graham · The Cerbat Gem

&Partners raised its holdings in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 28.0% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 1,038 shares of the company’s stock after acquiring an additional 227 shares during the quarter. &Partners’ holdings in Eli Lilly and Company were worth $558,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of LLY. Fairfield Bush & CO. bought a new stake in Eli Lilly and Company in the 1st quarter worth about $107,000. Roundview Capital LLC raised its holdings in shares of Eli Lilly and Company by 2.6% during the first quarter. Roundview Capital LLC now owns 2,056 shares of the company’s stock valued at $589,000 after purchasing an additional 53 shares during the last quarter. Merit Financial Group LLC bought a new position in Eli Lilly and Company during the first quarter valued at approximately $210,000. NewEdge Advisors LLC boosted its holdings in Eli Lilly and Company by 9.9% in the first quarter. NewEdge Advisors LLC now owns 53,052 shares of the company’s stock worth $15,193,000 after purchasing an additional 4,774 shares during the last quarter. Finally, Barometer Capital Management Inc. bought a new stake in Eli Lilly and Company in the 1st quarter worth approximately $561,000. Institutional investors own 81.38% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on LLY. UBS Group reissued a “buy” rating and set a $710.00 price target (up from $612.00) on shares of Eli Lilly and Company in a report on Friday, October 20th. TheStreet downgraded Eli Lilly and Company from a “b” rating to a “c+” rating in a research note on Monday, December 4th. Argus upped their price target on shares of Eli Lilly and Company from $470.00 to $620.00 and gave the company a “buy” rating in a research report on Tuesday, September 5th. Cantor Fitzgerald reissued an “overweight” rating and issued a $630.00 price objective on shares of Eli Lilly and Company in a report on Wednesday, November 15th. Finally, StockNews.com raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Friday, November 3rd. One investment analyst has rated the stock with a sell rating, two have given a hold rating and eighteen have given a buy rating to the company. According to MarketBeat, Eli Lilly and Company has a consensus rating of “Moderate Buy” and a consensus price target of $570.82.

Read Our Latest Report on Eli Lilly and Company

Insider Activity

In other news, CAO Donald A. Zakrowski sold 670 shares of Eli Lilly and Company stock in a transaction dated Monday, November 6th. The stock was sold at an average price of $571.10, for a total value of $382,637.00. Following the sale, the chief accounting officer now directly owns 4,708 shares of the company’s stock, valued at $2,688,738.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, CAO Donald A. Zakrowski sold 670 shares of the firm’s stock in a transaction on Monday, November 6th. The shares were sold at an average price of $571.10, for a total value of $382,637.00. Following the completion of the transaction, the chief accounting officer now directly owns 4,708 shares of the company’s stock, valued at $2,688,738.80. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, major shareholder Lilly Endowment Inc sold 215,000 shares of the company’s stock in a transaction on Wednesday, October 11th. The shares were sold at an average price of $605.44, for a total transaction of $130,169,600.00. Following the sale, the insider now directly owns 99,768,810 shares in the company, valued at approximately $60,404,028,326.40. The disclosure for this sale can be found here. Company insiders own 0.13% of the company’s stock.

Eli Lilly and Company Stock Down 4.0 %

Shares of LLY opened at $573.69 on Friday. The business’s 50 day moving average is $589.48 and its 200 day moving average is $529.77. The company has a current ratio of 1.05, a quick ratio of 0.82 and a debt-to-equity ratio of 1.59. Eli Lilly and Company has a 12-month low of $309.20 and a 12-month high of $629.97. The company has a market capitalization of $544.61 billion, a PE ratio of 103.93, a price-to-earnings-growth ratio of 3.64 and a beta of 0.33.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last released its quarterly earnings data on Thursday, November 2nd. The company reported $0.10 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.18. Eli Lilly and Company had a net margin of 15.55% and a return on equity of 48.12%. The firm had revenue of $9.50 billion for the quarter, compared to analysts’ expectations of $8.88 billion. Research analysts expect that Eli Lilly and Company will post 6.61 earnings per share for the current fiscal year.

Eli Lilly and Company Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 8th. Shareholders of record on Thursday, February 15th will be paid a $1.30 dividend. The ex-dividend date is Wednesday, February 14th. This represents a $5.20 annualized dividend and a yield of 0.91%. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.13. Eli Lilly and Company’s payout ratio is presently 81.88%.

Eli Lilly and Company Company Profile

(Free Report)